About the Study

The purpose of this study is to compare the effects and effectiveness of a new investigational formulation of Scopolamine in a nasal gel called DPI-386 Nasal Gel to placebo for the prevention of nausea and vomiting associated with motion sickness aboard an ocean-going boat. Scopolamine is an FDA (Food and Drug Administration) approved medication to prevent nausea associated with motion sickness and is available with a prescription as a transdermal patch.


This is a phase 3, randomized, double-blind, placebo-controlled study. Participants will be randomized at a ratio of 1:1 to either DPI-386 Nasal Gel or the matching placebo nasal gel. If you are eligible, you will be scheduled for a boat trip lasting approximately 4 hours leaving from and returning to the harbor at Marina Del Rey. Study medication will be administered one time in a single nostril while the ship is in harbor. There will be a total of 4 visits – 1 of the visits will be conducted at the clinic, 1 boat ride, and 2 Telehealth visits. You will not be charged for any of these visits and you may be compensated for your time. Compensation is available upon completion of each visit, up to $900 total.

If you are interested in participating in this study, click the button below:

If you would like more information about this study you can call us at (310) 586-0843

Our clinic is located at 12301 Wilshire Blvd Suite 200, Los Angeles, CA 90025


Santa Monica Clinical Trials adheres to a strict privacy policy that protects any information you share with us. We will not disclose your name or any other personally identifiable information without your permission.